Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib Study of CD22 CAR T Cells in R/R B Cell Malignancies
NCT04088890Phase 1Completed
- Start
- Sep 2019
- Primary completion
- Nov 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD22-CAR-T in acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (2 arms). Primary endpoints: Rate of Successful Manufacture of CD22 CAR T Cells, Incidence of Dose Limiting Toxicities at 28 days and 1 more. Started Sep 2019; status: completed.
02
Drugs
CD22-CAR-T
03
Conditions
acute lymphoblastic leukemia (ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04088890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04088890.